Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722179 | 1.00 | NAAA (0.36) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19721959 | 0.96 | NAAA (0.38) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19007876 | 0.93 | NAAA (0.40) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19721991 | 0.93 | NAAA (0.40) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19721901 | 0.93 | NAAA (0.40) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19755080 | 0.92 | NAAA (0.39) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19722182 | 0.92 | NAAA (0.39) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19722054 | 0.92 | NAAA (0.39) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19722160 | 0.92 | NAAA (0.39) | NAAAPKMMEN1HTTKMT2A | |
| SCHEMBL19722186 | 0.92 | NAAA (0.39) | NAAAPKMMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | NAAA 4846/4885PKM 2458/4885MEN1 90/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | NAAA 4714/4885PKM 2948/4885MEN1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.